Last reviewed · How we verify
stem cells infusion
Stem cell infusion delivers undifferentiated or progenitor cells that can differentiate, migrate to damaged tissues, and promote regeneration and immunomodulation.
Stem cell infusion delivers undifferentiated or progenitor cells that can differentiate, migrate to damaged tissues, and promote regeneration and immunomodulation. Used for Tissue regeneration and repair (specific indications vary by clinical application).
At a glance
| Generic name | stem cells infusion |
|---|---|
| Sponsor | University of Campania Luigi Vanvitelli |
| Drug class | Cell therapy |
| Modality | Small molecule |
| Therapeutic area | Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
Stem cells, typically derived from bone marrow, adipose tissue, or umbilical cord, are infused intravenously or locally to damaged or diseased tissues. These cells can differentiate into specialized cell types to replace damaged tissue, secrete paracrine factors that reduce inflammation and promote angiogenesis, and modulate immune responses to facilitate healing and tissue repair.
Approved indications
- Tissue regeneration and repair (specific indications vary by clinical application)
Common side effects
- Infusion-related reactions
- Infection
- Immune rejection
- Fever
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation (PHASE2)
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (PHASE2)
- Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) (PHASE1, PHASE2)
- Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II (PHASE1, PHASE2)
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
- BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- stem cells infusion CI brief — competitive landscape report
- stem cells infusion updates RSS · CI watch RSS
- University of Campania Luigi Vanvitelli portfolio CI